Gestodene-containing agent for transdermal administration
AssigneeSchering Corporation
InventorsClemens Guenther, Ulrich Taeuber, Karin Schmidt-Gollwitzer, Jutta Riedl, Johannes Wilhelm Tack
Life of this patent
Estimating the term…
Abstract
An agent for transdermal administration contains gestodene, optionally in combination with one or more estrogen(s).
Claims38
A pharmaceutical composition for transdermal administration comprising:
- gestodene and a pharmaceutically acceptable carrier for transdermal administration, and, optionally, an estrogenic compound,
- wherein the amount of gestodene dissolved or suspended in said pharmaceutically acceptable carrier is 0.01-25 wt. % and the amount of said estrogenic compound, if present dissolved or suspended in said pharmaceutically acceptable carrier is 0.01-25 wt. %.
An article for transdermal administration comprising:
- a pharmaceutical composition comprising gestodene and a pharmaceutically acceptable carrier for transdermal administration, and, optionally, an estrogenic compound;
- wherein the amount of gestodene dissolved or suspended in said pharmaceutically acceptable carrier is 0.01-25 wt. % and the amount of said estrogenic compound, if present, dissolved or suspended in said pharmaceutically acceptable carrier is 0.01-25 wt. %;
- and
- a transdermal therapeutic system wherein said composition is in said transdermal therapeutic system.
In a method of administering gestodene to a patient, the improvement comprising administering gestodene transdermally, optionally in combination with an estrogenic compound,
- wherein said gestodene and optional estrogenic compound are dissolved or suspended in a pharmaceutically acceptable carrier, and
- wherein the amount of gestodene dissolved or suspended in said pharmaceutically acceptable carrier is 0.01-25 wt. % and the amount of said estrogenic compound, if present, dissolved or suspended in said pharmaceutically acceptable carrier is 0.01-25 wt. %.
In a method of administering gestodene to a patient, the improvement comprising administering gestodene, optionally in combination with an estrogenic compound, by a transdermal therapeutic system,
- wherein said gestodene and optional estrogenic compound are dissolved or suspended in a pharmaceutically acceptable carrier, and
- wherein the amount of gestodene dissolved or suspended in said pharmaceutically acceptable carrier is 0.01-25 wt. % and the amount of said estrogenic compound, if present, dissolved or suspended in said pharmaceutically acceptable carrier is 0.01-25 wt. %.
Dependencies are inferred from the claim text.